Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...
Today Emergent BioSolutions (NYSE: EBS) announced it has received a delivery order valued at up to $21.5 million from the U.S. Department of War to ...
Self-administered injectable contraceptives have been available in the United States for more than two decades, yet a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback